Onderzoeksoutput

Onderzoeksoutput per jaar 2019 2019 2020 2021 2022

• 48 Citaties
• 4 h-index
• 7 Article
• 4 Meeting abstract (Journal)
• 1 Meeting abstract (Book)
• 1 Poster
• 1 Meer
  • 1 Letter

Onderzoeksoutput per jaar

Onderzoeksoutput per jaar

Zoekresultaten

• 2022

  Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring

  Locy, H., Verhulst, S., Cools, W., Waelput, W., Brock, S., Cras, L., Schiettecatte, A., Jonckheere, J., van Grunsven, L. A., Vanhoeij, M., Thielemans, K. & Breckpot, K., 11 feb 2022, In: Frontiers in Immunology. 13, 794175.

  Onderzoeksoutput: Article › peer review

  Open Access

  Bestand

  • Tumor-Infiltrating Lymphocytes 100%
  • Immunohistochemistry 54%
  • Breast Neoplasms 49%
  • Gene Expression 46%
  • Large-Core Needle Biopsy 10%
  3 Citaten (Scopus)

  41 Downloads (Pure)

• Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial

  Schwarze, J. K., Tijtgat, J., Awada, G., Cras, L., Vasaturo, A., Bagnall, C., Forsyth, R., Dufait, I., Tuyaerts, S., Van Riet, I. & Neyns, B., sep 2022, In: Journal for immunotherapy of cancer. 10, 9, blz. 1-13 13 blz., e005141.

  Onderzoeksoutput: Article › peer review

  Open Access
• 2021

  Abstract 962MO. A phase I clinical trial on intratumoral injection of autologous CD1C (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma

  Schwarze, J. K., Tijtgat, J., Awada, G., Cras, L., Dufait, I., Forsyth, R., Van Riet, I., Tuyaerts, S. & Neyns, B., 1 sep 2021, In: Annals of Oncology. 32, blz. S832-S833

  Onderzoeksoutput: Meeting abstract (Journal)

  Open Access

  • Clinical Trials, Phase I 100%
  • Myeloid Cells 84%
  • Dendritic Cells 73%
  • Melanoma 68%
  • Injections 47%

• Belgian twins born with the Gamma variant of SARS-CoV-2: Transplacental versus intrapartum transmission?

  Massa, H., Seyler, L., Cras, L. & Demuyser, T., sep 2021, In: European Journal of Obstetrics, Gynecology and Reproductive Biology. 264, blz. 383-384 2 blz.

  Onderzoeksoutput: Letter › peer review

  Open Access

• Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial

  Duerinck, J., Schwarze, J. K., Awada, G., Tijtgat, J., Vaeyens, F., Bertels, C., Geens, W., Klein, S., Seynaeve, L., Cras, L., D'Haene, N., Michotte, A., Caljon, B., Salmon, I., Bruneau, M., Kockx, M., Van Dooren, S., Vanbinst, A-M., Everaert, H., Forsyth, R. & 1 anderen, Neyns, B., jun 2021, In: Journal for immunotherapy of cancer. 9, 6, 11 blz., e002296.

  Onderzoeksoutput: Article › peer review

  Open Access

  • Nivolumab 100%
  • Clinical Trials, Phase I 95%
  • Blocking Antibodies 94%
  • Glioblastoma 78%
  • Monoclonal Antibodies 57%
  15 Citaten (Scopus)

• INTRA-CRANIAL ADMINISTRATION OF CTLA-4 AND PD-1 IMMUNE CHECKPOINT-INHIBITING MONOCLONAL ANTIBODIES IN RECURRENT GLIOBLASTOMA PATIENTS: A MULTI-COHORT ADAPTIVE PHASE I CLINICAL TRIAL

  Duerinck, J., Geens, W., Schwarze, J. K., Bertels, C., Tijtgat, J., Awada, G., Vaeyens, F., Cras, L., Nijland, L., Vanbinst, A-M., Everaert, H., Michotte, A., Janssen, T., Caljon, B., Cauwenbergh, T., Bruneau, M., Forsyth, R., Tuyaerts, S. & Neyns, B., nov 2021, In: Journal for immunotherapy of cancer. 9, 6, blz. 53-53 1 blz.

  Onderzoeksoutput: Article › peer review

  Open Access
  13 Citaten (Scopus)

• Overcoming the Challenges of High Quality RNA Extraction from Core Needle Biopsy

  Locy, H., Correa, R. J. M., Autaers, D., Schiettecatte, A., Jonckheere, J., Waelput, W., Cras, L., Brock, S., Verhulst, S., Kwan, K., Vanhoeij, M., Thielemans, K. & Breckpot, K., 22 apr 2021, In: Biomolecules. 11, 5, 19 blz., 621.

  Onderzoeksoutput: Article › peer review

  Open Access

  Bestand

  • Large-Core Needle Biopsy 100%
  • Biopsy 99%
  • Needles 79%
  • RNA 52%
  • Gene expression 37%
  3 Citaten (Scopus)

  181 Downloads (Pure)
• 2020

  65MO A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma

  Schwarze, J. K., Bertels, C., Awada, G., Tijtgat, J., Tuyaerts, S., Cras, L., Vaeyens, F., Vanbinst, A-M., Everaert, H., Michotte, A., Caljon, B., Olsen, C., Janssen, T., Van Dooren, S., Forsyth, R., Duerinck, J. & Neyns, B., dec 2020, In: Annals of Oncology. 31, S7, blz. S1443-S1443

  Onderzoeksoutput: Meeting abstract (Journal)

  • Ipilimumab 100%
  • Nivolumab 99%
  • Clinical Trials, Phase I 84%
  • Glioblastoma 69%
  • Organized Financing 38%

• An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma

  Keukeleire, S. D., Schwarze, J., Awada, G., Everaert, H., Van Binst, A. M., Cras, L., Neyns, B. & Aspeslagh, S., 2020, In: Melanoma Research. 30, 5, blz. 524-527 4 blz.

  Onderzoeksoutput: Article › peer review

  • Melanoma 100%
  • pembrolizumab 89%
  • Proteins 44%
  • Lymph Nodes 42%
  • Watchful Waiting 42%
  5 Citaten (Scopus)

• Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial

  Schwarze, J. K., Awada, G., Cras, L., Tijtgat, J., Forsyth, R., Dufait, I., Tuyaerts, S., Van Riet, I. & Neyns, B., dec 2020, In: Vaccines. 8, 4, blz. 1-16 16 blz., 670.

  Onderzoeksoutput: Article › peer review

  Open Access

  • avelumab 100%
  • Dendritic Cells 90%
  • Ipilimumab 77%
  • Nivolumab 77%
  • Tumors 56%
  9 Citaten (Scopus)
• 2019

  A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)(+) myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors.

  Schwarze, J. K., Awada, G., Cras, L., Forsyth, R., Van Riet, I. & Neyns, B., 20 mei 2019, In: Journal of Clinical Oncology. 37, 15, e14012.

  Onderzoeksoutput: Meeting abstract (Journal)

• A phase Ib clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors.

  Schwarze, J. K., Awada, G., Cras, L., Forsyth, R., Van Riet, I. & Neyns, B., mei 2019, Journal of Clinical Oncology. American Society of Clinical Oncology, e14012

  Onderzoeksoutput: Meeting abstract (Book)

• A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells plus talimogene laherparepvec (T-VEC) in patients with advanced melanoma

  Schwarze, J. K., Awada, G., Cras, L., Dufait, I., Forsyth, R., Van Riet, I. & Neyns, B., 6 nov 2019, In: Journal for immunotherapy of cancer. 7

  Onderzoeksoutput: Meeting abstract (Journal)

• synchronous presentation of endometrioid carcinoma of the ovary and carcinosarcoma of the uterus

  Sahebali, S., Cras, L., Lefesvre, P., Cosijns, S. & joris, S., 18 okt 2019.

  Onderzoeksoutput: Poster